Mangalam Drugs And Organics Limited — Results, 14-05-2026: Integrated Filing- Financial

Mangalam Drugs & Organics announced its financial results for the year ended March 31, 2026.

1. **Financial Performance:** Total revenue from operations for the year declined by 26.89% year-over-year, settling at 232.13 Cr compared to 317.58 Cr previously. The company's primary business is 'Manufacturing of Bulk Drugs'.

2. **Profitability and EPS:** The company reported a net loss of 44.40 Cr for the year, a significant shift from the net profit of 6.72 Cr in the prior year. Basic EPS consequently dropped to (28.05) from 4.25.

3. **Growth Drivers & Expense Trends:** The substantial decline in revenue was the primary factor behind the net loss. While operating expenses saw some reduction, it wasn't enough to offset the revenue contraction. Finance costs, however, increased year-over-year.

4. **Final Lens for Investors:** These results reflect a period of weak financial momentum for the company.